A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2)Ralph V. Boccia, James R. Berenson, Alberto Bessudo et al.|Clinical Lymphoma Myeloma & Leukemia|2017Cited by 19
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumorsRobert M. Jotte, Robert Ilaria, Daniel D. Von Hoff et al.|Investigational New Drugs|2014Cited by 10
Novel organic arsenic molecule darinaparsin: Development of IV and oral formsIzidore S. Lossos, Wilson H. Miller, Michael Craig et al.|Journal of Clinical Oncology|2009Cited by 5
Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase inhibitor, in patients with advanced colorectal cancer.Derek J. Jonker, Chiang Li, Rachel Goodwin et al.|Journal of Clinical Oncology|2015Cited by 4
A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2)Ralph V. Boccia, James R. Berenson, Alberto Bessudo et al.|Blood|2016Cited by 4